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Abstract 
Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and 
disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all 
increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac 
electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile 
amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural 
pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac 
electrophysiological changes include up- and down-regulation of specific  ion channel expression and intracellular Ca
2+ overload which 
promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the 
pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and 
elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and 
antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, 
including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly 
patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful 
attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must 
be individualized and tailored to each patient’s physiology, disease processes, and medication regimen. 
J Geriatr Cardiol 2011; 8: 184−194. doi: 10.3724/SP.J.1263.2011.00184 
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1  Issues  of  global  aging
   
Elderly people constitute a larger segment of the 
population today than at any other time in history. In 1900, 
only 4% of the population in the United States was 65 or 
older. In 2000, more than 40 million people were in that age 
group, representing nearly 13% of the population. By 2030, 
when the last wave of baby boomers reaches the age of 65, 
elderly people are expected to constitute over 20% of the 
U.S. population.
[1] 
Moreover, human aging is a global issue. Based on 
census and population projections from 1950 to 2050, there 
has been a worldwide transformation of the distribution of 
the population by age, from a population pyramid to a  
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population dome (Figure 1). This trend applies to both male 
and females, in developing countries as well as in developed 
countries.
[2] In fact, the large population in the developing 
world contributes significantly to the transformation in 
demographics. These trends in the global patterns of aging 
have important implications for the current and future 
incidence and prevalence of many health conditions. With 
the advance in overall age comes an increase in the 
incidence of cardiovascular diseases, including cardiac 
arrhythmias. Global aging has important implications for 
health care delivery, as age-related physiological changes 
are frequently overlooked when treatment options are 
considered and may result in unnecessary adverse outcomes. 
This review will focus on issues pertaining to the 
pharmacologic treatment of cardiac arrhythmias in the 
elderly population. 
2  Aging  and  cardiac  arrhythmias 
The prevalence of cardiac diseases, including cardiac 
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Figure 1.    World population by age and sex: 1950–2050. Distribution of the world population by age and sex from 1950 (top panel) to 2000 
(middle panel) and 2050 (bottom panel). With global aging, the world population is being transformed from a population pyramid to a 
population dome. These changes occur not only in developed countries (grey) but also in developing countries (white). Adopted from United 
Nations and United States Census Bureau.
[1,2] 
 
arrhythmias, increases with age.
[3,4] Increased frequencies of 
supraventricular and ventricular ectopies have been reported 
in elderly patients.
[4] Additionally, elderly patients have a 
heightened propensity to develop certain arrhythmias, 
including atrial fibrillation,
[5] sudden cardiac death,
[6] and 
bradyarrhythmias requiring pacemaker placement.
[7] Results 186  Lee HC et al. Using antiarrhythmic drugs in elderly patients 
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from the ATRIA (AnTicoagulation and Risk Factors in 
Atrial fibrillation) study showed that there is an exponential 
increase in the prevalence of atrial fibrillation after the age 
of 60 for both men and women, with over 10% of people 
older than 80 years of age affected.
[8] Based on these results, 
it is projected that by 2050, the majority of patients with 
atrial fibrillation will be 80 years or older. Similarly, the 
incidence of sudden cardiac death in the general population 
shows an exponential increase after 55 years of age, peaking 
in the seventies and eighties. This affects both men and 
women, with women accounting for 43% of sudden cardiac 
death cases.
[9,10] There is also a remarkable age-related 
increase in bradyarrhythmias, both in sinus nodal 
dysfunction and in atrioventricular (AV) blocks. The 
incidence of first time pacemaker implantation increases 
substantially after the age of 60, peaking in the seventies 
and leveling off in the eighties.
[11,12] 
3  Changes in cardiac electrophysiology with 
aging 
Cardiac electrophysiological properties change with age, 
and it is essential to differentiate between normal, 
physiologic consequences of aging versus abnormal, 
pathological transformations. First, intrinsic heart rate 
decreases with age.
[13] Heart rate response is blunted with 
advanced age, though excessive sinus pauses are not 
considered physiologic.
[14] Second, the PR interval becomes 
prolonged with age. First degree AV block is common 
among elderly people, but second and third degree AV 
blocks are abnormal. These changes are associated with AH 
prolongation without alteration of the HV interval.
[15] Third, 
conduction system changes in the form of right bundle 
branch block (RBBB) are more common in elderly patients 
and are not associated with cardiac morbidity or mortality, 
but the presence of left bundle branch block (LBBB) in 
older patients is frequently an indication of the presence of 
underlying cardiac disease
[4] and is associated with adverse 
outcomes.
[16] Fourth, atrial and ventricular ectopies are 
known to increase with age, but atrial fibrillation and 
ventricular tachycardia should not be considered normal.
[17,18] 
Fifth, age-related non-specific ST-T wave changes are 
common, but the presence of Q waves is seldom normal. 
Sixth, the QT interval increases with age, and this is true for 
both men and women.
[19] Usually, men have shorter QT 
intervals compared to women at the same age, but QT 
intervals are similar between men and women in the 
post-menopausal years.
[19] 
Normal aging is associated with a reduced autonomic 
response to stress, including decreased baroreflex buffering
[20] 
and depressed heart rate variability.
[21] There is an increase 
in the prevalence of orthostatic hypotension and supine 
hypertension with age; however, the presence of 
baroreceptor and autonomic failure is abnormal.
[22] Because 
of these alterations, the cardiac electrophysiological changes 
that occur with age reduce the margin of functional reserve 
and render the aging heart more susceptible to the 
development of electrophysiological abnormalities. In addition, 
the age-related cardiac changes which include ventricular 
hypertrophy, senile amyloidosis, cardiac valvular degenerative 
changes and annular calcification, fibrous infiltration of the 
conduction system, and loss of natural pacemaker cells 
could also have profound direct and indirect effects on the 
development of arrhythmias.   
4    Changes in cardiac ion channels with aging 
The age-related electrocardiogram (ECG) and action 
potential changes are associated with changes in the 
properties and activities of specific ion channels (Table 1).
[23,24] 
Among the inward currents, the voltage-gated sodium 
channel is unaltered with age,
[25] but the L-type Ca
2+ 
currents (ICaL) are increased with delayed inactivation in the 
ventricles,
[26] while becoming significantly reduced by more 
than 40% in the atria.
[27] On the other hand, among the 
repolarizing currents in the ventricles, the transient outward 
K
+ currents (Ito)
[24,27] and the ATP-sensitive K
+ currents 
(IKATP) are reduced.
[28] These, together with the enhanced 
ICaL, result in lengthened action potential durations and 
prolonged QT intervals. Meanwhile, the strong inward 
rectifier K
+ currents (IK1) are unchanged.
[29]  
 
Table 1.    Change in cardiac ionic currents with old age. 
Currents  Change in aging 
INa  Atria: ↔, Sinus node: ↓ 
ICaL 
 
Ventricles:↑, delayed inactivation Atria:↓ by 40%,
Sinus node: ↓ 
Ito  ↓ 
IKATP  ↓ 
IKur  Atria:↑ 
IK1  ↔ 
INCX  ↑ 
SERCA-2  ↓ 
Cx-43  Sinus node: ↓ 
HCN4  Sinus node:↓ mRNA 
APD  Atria and ventricles: ↑ 
INa:  voltage-gated sodium currents; ICaL: L-type calcium currents; Ito: 
transient outward potassium currents; IKATP: ATP-sensitive potassium 
currents; IKur,: ultra-rapid delayed rectifier potassium currents; IK1: strong 
inward rectifier potassium currents; INCX: sodium-calcium exchange 
currents; SERCA-2: sarcoplasmic reticulum calcium pump; Cx-43: 
connexin-43; HCN4: hyperpolarization-activated cyclic nucleotide-gated 
channel 4; APD: action potential duration; ↔: unalter; ↑: increase; ↓: 
decrease. Lee HC et al. Using antiarrhythmic drugs in elderly patients  187 
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In the atria, the ultra-rapid delayed rectifier K
+ currents 
(IKur) are enhanced.
[27] Since IKur is atrial-specific, the 
upregulation in IKur may render the aging atria more 
susceptible to the development of atrial fibrillation.
[30] In the 
sinus node, there is significant age-related electrical and 
structural remodeling in the form of downregulation of 
sodium channels,
[31] L-type calcium channels,
[32] and 
connexin-43,
[33] as well as an increase in fibrosis.
[34] These 
ionic changes may lead to the development of sinus node 
dysfunction in the elderly patient.   
Aging has also been shown to be associated with a 
downregulation in the mRNA expression of HCN4, which 
encodes If,
[35] but reduced If current has not been 
demonstrated. In addition, the aging myocardium is 
associated with abnormal intracellular Ca
2+ regulation as 
expression of the SERCA-2 Ca
2+ pump is reduced 
[36,37] while  
that of the sodium-calcium exchanger is increased.
[38] This is 
very important because the electrical and structural 
remodeling of the aging heart suggest that the therapeutic 
targets of antiarrhythmic drugs, i.e., the cardiac ion channels, 
change with age. In addition to these age-related alterations in 
the ionic channels, the pharmacokinetics and pharmaco-
dynamics of antiarrhythmic drugs also vary with age. 
5  Changes in antiarrhythmic drug pharma-
cokinetics with age: Drug-body interactions 
Pharmacokinetics is defined as the handling of a drug 
within the body, including its absorption, distribution, 
metabolism, and elimination. A number of age-related 
physiological changes that occur with aging may affect drug 
disposition in the body (Figure 2).   
 
 
 
Figure 2.  Age-related changes in pharmacokinetics of antiarrhythmic drugs. Diagrammatic representation of age-related changes in the absorption, 
distribution, metabolism, and elimination of antiarrhythmic drugs. GI: gastrointestinal; GFR: glomerular filtration rate; CrCl: creatinine 
clearance; ↔: unalter; ↑: increase; ↓: decrease. 188  Lee HC et al. Using antiarrhythmic drugs in elderly patients 
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5.1  Absorption  
With age, there is a decrease in gastric acid secretion that 
may reduce the dissolution of tablets and the solubility of 
basic drugs.
[39] Antiarrhythmic drugs are weak bases, so 
there may be reduced gastric solubility with age, but the 
effects are small. The gastric emptying rate is somewhat 
delayed as there is reduced gastrointestinal motility, 
decreased mucosal surface area, and reduced splanchnic 
blood flow, which decreases by 30%−40% between ages 20 
and 70.
[40,41] Despite these changes, the oral absorption of 
antiarrhythmic drugs is not significantly affected by aging, 
probably because most of these drugs are absorbed 
passively.
[39,42] However, bioavailability can be significantly 
affected by the decrease in first-pass intestinal wall/hepatic 
extraction with aging, resulting in enhanced systemic 
bioavailability for drugs such as propranolol and 
lidocaine.
[43,44] 
5.2  Distribution  
Drug distribution can be profoundly affected by some of 
the physiological changes that occur as patients get older. 
Between ages 20 and 70, body fat as a proportion of body 
weight rises from 18% to 36% in males and from 33% to 
45% in females, while there is an overall reduction in lean 
body mass of 20% in men and 12% in women during those 
years.
[39,45,46] These changes significantly increase the 
volume of distribution of fat soluble drugs like amiodarone. 
At the same time, there is a reduction of 8% in total body 
water, thereby reducing the volume of distribution for water 
soluble drugs like digoxin.
[47]  
In addition, the serum level of α-1-glycoprotein, which 
binds weak bases such as antiarrhythmic drugs, increases in 
the elderly, causing a reduction in the free fraction of the 
drugs and in the effective volume of distribution while 
simultaneously increasing drug plasma concentration.
[48] 
Plasma albumin tends to be reduced in the elderly.
[49,50] 
Weakly acidic drugs, such as warfarin, normally bind to 
albumin. Thus, the reduced plasma albumin may result in a 
more intense drug effect with age, making the elderly 
patient more susceptible to bleeding complications.
[42] 
5.3  Metabolism  
Drugs are metabolized in the liver by two types of 
reactions, namely phase I oxidative reactions and phase II 
conjugative/synthetic reactions.
[51] Most phase I reactions 
are mediated by cytochrome P450 (CYP) monooxygenases.
[52] 
Table 2 shows the five CYP isozymes that are important for 
the metabolism of clinically relevant antiarrhythmic drugs. 
CYP2D6 and CYP3A4 in particular are two of the most 
important isozymes for the metabolism of drugs, including 
antiarrhythmics.
[42,52,53] Quinidine, disopyramide, lidocaine, 
mexiletine, flecainide, propafenone, amiodarone, verapamil 
and metoprolol are all dependent on the activities of these 
enzymes for metabolism. After the age of 30, there is a 1% 
per year decline in liver blood flow and liver mass, 
correlating with a significant age-related reduction in phase 
I reactions.
[54–56] In contrast, the activities of phase II 
reactions, through which an acetyl group or a sugar is 
conjugated to the drug to enhance its polarity, water 
solubility and hence excretion via the kidneys, are relatively 
unaffected by age.
[54,57] Nevertheless, the reduction in liver 
function may reduce the clearance and increase the 
half-lives of antiarrhythmic drugs metabolized by the liver, 
such as quinidine, propafenone, amiodarone. The reduction 
in hepatic blood flow with age is also known to significantly 
reduce the clearance of high hepatic extraction ratio drugs, 
such as lidocaine and propranolol, which require dose 
adjustments according to age to minimize the risk of 
adverse effects.
[58–62] 
 
Table 2.  Clinically important cytochrome P450 (CYP) isozymes 
and substrates. 
CYP1A2 CYP2C9  CYP2C19  CYP2D6  CYP3A4 
Mexiletine Phenytoin Phenytoin Flecainide  Quinidine 
Caffeine Warfarin  Diazepam  Encainide  Disopyramide
Theophylline   Propafenone  Lidocaine 
     Mexiletine  Amiodarone 
     Metoprolol  Verapamil 
5.4  Elimination  
Normal aging is associated with a significant reduction in 
kidney size as well as in the number and size of nephrons, 
while the proportion of sclerotic glomeruli increases. With 
age, glomerular filtration rate, tubular secretion, and renal 
blood flow decrease approximately by 0.5%, 0.5% and 1% 
per year, respectively, after the age of 20.
[42,63,64] Hence, in 
an 80-year-old patient, the loss of renal function leads to a 
significant accumulation of renally-cleared antiarrhythmic 
drugs such as digoxin, procainamide, N-acetyl procainamide 
(NAPA), sotalol, and dofetilide. In addition, because of the 
reduction in muscle mass with advancing age, serum 
creatinine should not be used as a marker for estimation of 
renal function.
[65] A serum creatinine of 1.0 is associated 
with a normal creatinine clearance (CrCl) for a 35-year-old 
patient, an adequate but reduced CrCl in a 65-year-old 
patient, and an abnormally low CrCl in an 85-year-old 
patient.
[63] An equation such as the following should be used 
to estimate CrCl
[66,67]: CrCl = ((140−age) × (wt in kg)) / (72 
× sCr). 
For women, CrCl as calculated in the equation above Lee HC et al. Using antiarrhythmic drugs in elderly patients  189 
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should be multiplied by a factor of 0.85. 
The age-related pharmacokinetic changes associated with 
antiarrhythmic drugs are summarized in Table 3 and show 
several general features. Aging is associated with reduced 
clearance of many antiarrhythmic drugs, resulting in an 
increase in drug half-lives. Maximum drug concentration 
may also increase, potentially augmenting the risk of drug 
toxicity. The volume of drug distribution also changes with 
age and depends on whether the drug is lipophilic or 
hydrophilic. Thus, most antiarrhythmic drugs will need 
dosage adjustments in the elderly patient. 
 
Table 3.  Age-related pharmacokinetic changes with antiarrhythmic 
drugs. 
Pharmacokinetics 
Drug 
tmax C max t 1/2  Vd CL 
Digoxin  ↑  NA  ↑  ↓  ↓↓ 
Disopyramide  ↔  ↑  ↑ ↔  NA  ↓ 
Quinidine NA  NA  ↑  ↔  ↓ 
Lidocaine  ↔  ↑  ↑  ↑  ↔ ↓ 
Mexiletine  ↔  ↔ ↑  ↔ ↑  NA  ↔ ↓ 
Flecainide NA  NA  ↑  ↑  ↓ 
Propafenone NA  ↔ ↑  ↑  NA  ↓ 
Sotalol  ↔  ↑  ↑  ↔  ↓↓ 
Dofetilide  ↔  ↑  ↑  ↔  ↓↓ 
Amiodarone NA  NA  ↑  ↑  ↓ 
Dronedarone  ↔  ↑  ↑  ↑  ↓ 
Verapamil  ↔ ↑  ↔ ↑  ↑  ↔  ↓ 
tmax: time to maximum plasma concentration; Cmax: maximum plasma 
concentration; t1/2: half life; Vd: volume of distribution; CL: clearance; NA: 
not available; ↔: unalter; ↑: increase; ↓: decrease. 
6  Changes in pharmacodynamics of anti- 
arrhythmic drugs with aging: Drug-disease 
interactions 
Pharmacodynamics is defined as the effects of the drugs 
on the body. The physiological changes associated with 
aging can profoundly affect drug pharmacodynamics and 
make the elderly patient more susceptible to potential 
adverse effects of antiarrhythmic drugs. Aging is associated 
with reduced cardiac reserve, rendering the heart more 
susceptible to heart failure.
[68–70] Baroreceptor sensitivity is 
blunted, increasing the risk of orthostatic hypotension.
[71,72] 
There is reduced sensitivity to agonists and antagonists, 
causing a decreased response to adrenergic drugs.
[73–75] 
Deterioration in sinus and AV nodal function in the elderly 
increases the propensity for developing significant 
bradycardia and heart blocks.
[4,76] Also, the increase in 
sensitivity to anticoagulating agents heightens the risk of 
bleeding in the elderly patient.
[77–80] 
Specifically, pertaining to antiarrhythmic drugs, the 
age-related changes in pharmacodynamics include reduced 
sensitivity to blockers
[73–75] as well as increased sensitivity 
to Class I antiarrhythmic drugs in terms of sinus nodal 
function and electrical impulse conduction.
[51] Also, 
antiarrhythmic drugs have greater avidity in binding to 
cardiac tissue in patients with ischemic heart disease and 
cardiomyopathy. Finally, impaired homeostatic mechanisms 
increase the risks of potential adverse drug effects such as 
orthostasis, urinary retention, constipation, falls, and 
bleeding.
[71,77,78,80–83] 
Some of the important antiarrhythmic drug-disease 
interactions in geriatric patients are listed in Table 4. Most 
antiarrhythmic drugs are negative inotropic agents. 
Disopyramide, flecainide, and sotalol are known to cause 
acute decompensation in patients with poor ventricular 
function.
[84] Class I antiarrhythmic drugs, blockers, and 
Ca
2+ channel blockers can precipitate heart block or sinus 
bradycardia in the elderly. Sotalol and propafenone are 
blockers and can exacerbate bronchospasm.
[85] Since lung 
function declines throughout adult life even in healthy 
persons and may accelerate after age 70, elderly patients 
are more vulnerable to such adverse effects.
[86]  
Disopyramide has anticholinergic properties and is known 
to worsen symptoms of prostatism, which is prevalent in 
elderly men.
[81] In the presence of hypokalemia, digoxin 
can exacerbate the development of life-threatening 
ventricular arrhythmias. Due to reduced renal function, 
elderly patients are more susceptible to developing 
digitalis toxicity.
[87,88] Class I antiarrhythmic drugs in 
patients with coronary artery disease and myocardial 
infarction are pro-arrhythmic and may cause sudden 
death.
[89,90] These conditions are more common with 
advanced age, precluding the use of these medications in 
many elderly patients. Lastly, antiarrhythmics with 
vasodilator properties, such as procainamide, quinidine, and 
sotalol, can exacerbate orthostatic hypotension and 
precipitate falls in the elderly.
[82,83] 
 
Table 4.  Important antiarrhythmic drug-drug interactions in 
elderly patients. 
Underlying disease  Drugs  Adverse effects 
CHF  Disopyramide, flecainide,   
sotalol 
Decompensation
 
Cardiac conduction   
disorders 
Class 1 drugs, β and Ca
2+  
blockers 
Heart block 
 
COPD Sotalol  Bronchospasm 
Prostate hypertrophy  Disopryramide Urinary  retention
Hypokalemia Digoxin  Arrhythmias 
CAD  Class 1 drugs  Proarrhythmia 
Postural hypotension
 
β and Ca
2+ blockers, quinidine,   
procainamide 
Falls 
 
CHF: congestive heart failure; COPD: chronic obstructive pulmonary 
disease; CAD: coronary artery disease. 190  Lee HC et al. Using antiarrhythmic drugs in elderly patients 
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7  Issues with polypharmacy: Drug-drug 
interactions 
In addition to the above, polypharmacy is an important 
problem in the elderly. Both the prevalence of adults with 
prescriptions and the number of prescriptions per person 
increase with age. More than 75% of elderly people in the 
community use one or more medications, with an average of 
eight prescriptions per elderly patient.
[91]    
The pervasiveness of polypharmacy makes the elderly 
vulnerable to adverse drug-drug interactions, including 
those involving antiarrhythmic drugs. Class I antiarrhythmic 
drugs are all sodium channel blockers, but many of them, 
especially the Class IA drugs, also have potassium channel 
blocker effects, including blockade of Ito, IKr, and IKS.
[84,92] 
The potassium channel blocker effects confer the QT 
prolonging properties of these drugs, which are known to be 
associated with torsade de pointes.
[93] The Class IC drugs 
have also been shown to block IKur, which may account for 
their comparative effectiveness in treating atrial arrhy-
thmias.
[84,92] In addition, the Class IA drugs have vagolytic 
effects as well as adrenergic receptor blocking effects. 
Propafenone is a propranolol analog and has weak blocker 
properties. All of these “off-target” effects of Class I 
antiarrhythmic drugs may cause important adverse 
consequences when these drugs accumulate.   
All Class I antiarrhythmics except procainamide are 
metabolized in the liver by CYP3A4 or CYP2D6.
[94] 
Procainamide is acetylated in the liver to form NAPA and is 
subsequently excreted by the kidneys through active tubular 
secretion, which can be inhibited by cimetidine and 
trimethoprim. Quinidine is metabolized by CYP3A4, but it 
is also a potent inhibitor of CYP2D6 and has complex 
interactions with propafenone metabolism.
[95] Drugs that 
inhibit the CYP system, such as cimetidine, ketoconazole, 
and macrolide antibiotics, also inhibit clearance of Class I 
antiarrhythmic drugs. Grapefruit juice inhibits intestinal 
wall CYP3A4 and CYP1A2 and potentiates the effects of 
drugs that are cleared by these enzymes.
[96] On the other 
hand, rifampin, glucocorticoids, phenytoin, ethanol, and 
phenobarbital induce CYP3A4, which increases quinidine, 
disopyramide, amiodarone, lidocaine, and verapamil clearance. 
Quinidine, amiodarone, and dronedarone are inhibitors of 
P-glycoprotein, which is required for renal excretion of 
digoxin, thereby augmenting digoxin levels.
[97]  
Class III antiarrhythmic drugs are potassium channel 
blockers, but amiodarone and dronedarone are promiscuous, 
inhibiting the voltage-gated sodium channel, the L-type 
Ca
2+ channel, and β-adrenergic receptors.
[84,92] Amiodarone 
and dronedarone are hepatically metabolized, while sotalol 
and NAPA are eliminated by the kidney. Although dofetilide 
is mostly cleared by the kidney, 20% is metabolized by 
CYP3A4, so its level can be altered by drugs, such as 
ketoconazole, that modulate CYP3A4 activities. Also, 
cimetidine inhibits renal cationic secretion of dofetilide and 
prolongs its half-life.
[98] Other agents that inhibit renal 
cationic secretion may have similar effects. Amiodarone is a 
potent inhibitor to a number of drug metabolizing enzymes 
and drug transporters, including CYP3A4, CYP2C9, and 
P-glycoprotein. Hence, the substrate of these enzymes, 
which include a variety of drugs commonly used in the 
geriatric population, will need appropriate dose adjustment 
when used concomitantly with amiodarone.
[99]   
Adenosine has a very short half-life and is removed by 
cellular uptake. Its effects are augmented by dipyridamole, 
which blocks adenosine deaminase, allowing adenosine to 
accumulate extracellularly. Theophylline counteracts the 
effects of adenosine by potentiating intracellular cAMP. 
Hence, when using adenosine, it is crucial that the patient is 
not taking dipyridamole or theophylline, which will 
profoundly alter the effects of adenosine.
[100–102] Digoxin is a 
Na/K pump inhibitor and is an inotropic agent that activates 
the Na/Ca exchanger, leading to an increase in intracellular 
Ca
2+.
[87] Digoxin is removed via the kidney and its secretion 
is mediated by P-glycoprotein. Thus, drugs such as 
quinidine that inhibit P-glycoprotein cause an increase in 
digoxin levels.
[97] The dose of digoxin should be adjusted 
based on the other drugs that the elderly patient is taking 
and plasma levels of digoxin should be monitored. A recent 
prospective cohort study of 2030 elderly patients showed 
that the risk of digoxin toxicity requiring hospitalization is 
increased more than four-fold in those with a history of 
recent hospitalization (within two months).
[88] This under-
scores the prevalence of medication misadventures in the 
elderly population, which imposes a significant burden on 
the health care system,
[103] and the importance of paying 
close attention to evaluate adherence, prescribing, and 
adverse drug reactions in the management of elderly 
patients’ medical care. 
8  Summary 
To conclude, what do we need to know about 
antiarrhythmic drug therapy in elderly patients? The first 
thing to know is the patient population. Elderly patients are 
avid consumers of medications, which increases the risk of 
drug-drug interactions. Moreover, the elderly are subject to 
significant age-related physiological changes that may alter 
the effects of individual drugs. The second thing to know is 
the antiarrhythmic drugs. Age-related alterations in drug Lee HC et al. Using antiarrhythmic drugs in elderly patients  191 
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pharmacokinetics, in hepatic metabolism, and in renal 
elimination can be pronounced for some drugs and are often 
under-appreciated. The third thing to know is that the use of 
antiarrhythmic drugs in elderly patients must be individualized. 
Potential drug-drug and drug-disease interactions are 
common and must be scrutinized for each patient. All these 
issues may have a significant impact on the health-related 
quality of life in the elderly. 
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